- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
Merck's (MRK) Keytruda treatment improved the survival rate of patients with bladder cancer who previously underwent treatment.
Look for solid companies showing life.